Cell Line

The Dual Epitope Anti-BCMA CAR-T Cells are generated via high-titer lentiviral transduction of human primary CD4⁺and CD8⁺ T cells <u>with the SIN Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ) (#78783)</u>. These ready-to use CAR (chimeric antigen receptor)-T cells express an anti-BCMA CAR consisting of a ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (VHH1 and VHH2) linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

The Dual Epitope Anti-BCMA CAR-T Cells are generated via high-titer lentiviral transduction of human primary CD4⁺and CD8⁺ T cells <u>with the SIN Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ) (#78783)</u>. These ready-to use CAR (chimeric antigen receptor)-T cells express an anti-BCMA CAR consisting of a ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (VHH1 and VHH2) linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

The Membrane-Bound TNFα CHO Cell Line is a clonal CHO cell line stably expressing human membrane-bound TNFα (tumor necrosis factor alpha) driven by an EF1a promoter. The cells were generated by transduction with Membrane-Bound TNFα (mTNFα) Lentivirus (#78955).

Androgen Luciferase Reporter 22RV1 Cell Line is a human 22Rv1 cell line with a stably integrated Firefly luciferase reporter under the control of an androgen response element. This cell line monitors the activity of the androgen receptor signaling pathway. This cell line has been validated in cellular assays involving the inhibition of 5α-Dihydrotestosterone (5-DHT)-induced reporter activation by AR (androgen receptor) antagonists such as Enzalutamide, Bicalutamide, Mifepristone and ARCC-4.

The HLA-C*08:02 K562 Cell Line is an engineered human lymphoblast K562 cell line expressing human HLA-C*08:02 driven by an EF1a promoter. This cell line was generated by transduction with HLA-C*08:02 Lentivirus (BPS Bioscience #78930). This cell line has been validated by flow cytometry and co-culture assays with Jurkat cells expressing KRAS G12D, in the presence of wild type and mutant KRAS peptides

MAGE-A4 CD8⁺ NFAT-Luciferase Reporter Jurkat Cell Line was generated from T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556</a>) by overexpression of human CD8 (NM_001768.6) and a MAGE-A4 (Melanoma-associated antigen 4)-directed TCR using lentiviral transduction (CD8a Lentivirus #78648 and MAGE-A4-Specific TCR Lentivirus #78935). This human MAGE-A4 TCR specifically recognizes an antigen corresponding to MAGE-A4 peptide, amino acids 230-239 (GVYDGREHTV).

The Untransduced T Cells (NY-ESO-1 TCR-T Negative Control) were produced by mock lentiviral transduction of human primary CD4⁺ and CD8⁺T cells. These cells are subjected to comparable manipulations as TCR (T cell receptor)-T cells: activation, spinoculation (without lentivirus), and antigen specific stimulation. These T cells are designed as negative controls in experiments using lentivirus-transduced TCR-T cells, such as NY-ESO-1 (c259) TCR-T Cells (BPS Bioscience #78990</a>).

The NY-ESO-1 (c259) TCR-T Cells are generated by high-titer lentiviral transduction of human primary CD4⁺ and CD8⁺ T cells <u>with NY-ESO-1-Specific TCR Lentivirus (Clone c259) (#78676)</u>. These ready-to-use TCR (T cell receptor) -T cells express the human TCR clone c259, that specifically recognizes the antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1). These TCR-T cells have been validated by flow cytometry (to determine the TCR expression) and co-culture assays (IFN-γ staining and degranulation).

IL-6 Responsive Luciferase Reporter HEK293 Cell Line is a HEK293 cell line designed to monitor the IL-6 (interleukin 6)/IL-6 receptor interaction. These cells express endogenous IL-6 receptor (IL-6R and gp130) and were engineered to express firefly luciferase under the control of a STAT response element. This cell line has been validated to respond to human interleukin-6 (IL-6), IL-27, and further functional validation experiments showed that IL-6-induced luciferase activity was decreased by the JAK inhibitor CP 690,550 and by an anti-IL-6R neutralizing antibody.